We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Agent Could Enhance Effectiveness of Radiotherapy

By MedImaging International staff writers
Posted on 27 May 2014
Print article
Scientists have demonstrated the potential of a drug to enhance the effectiveness of radiotherapy in stopping tumor growth.

There is increasing interest in using the body’s own immune system to attack tumor cells—an approach that can be very effective without the side effects linked with traditional chemotherapy.

Skin cancers have been effectively treated using a topical cream, imiquimod, which recruits immune cells through a molecule called toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially damaging substances. Earlier, researchers from the University of Manchester (part of the Manchester Cancer Research Centre; UK) have shown that they can also trigger the immune system into producing an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

Working with AstraZeneca (London, UK) and Dainippon Sumitomo Pharma (Osaka, Japan), the British group of investigators have examined at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they evaluated DSR-6434 on its own and in combination with radiotherapy and gauged the effect on the primary tumor and the number of secondary tumors in the lungs.

Prof. Ian Stratford, from Manchester Pharmacy School, who, with Prof. Tim Illidge, who led the study, which was published online January 2014 in the International Journal of Cancer, said, “We have already seen a strong immune system response from other immunotherapy agents in combination with radiation--this new agent appears to be even more potent.”

The investigators revealed that giving DSR-6434 combined with radiotherapy led to tumor shrinkage and increased long-term survival. They discovered that the combination treatment also reduced the occurrence of secondary lung tumors. “It looks like there’s good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumors. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients,” added Prof. Stratford.

Related Links:

Manchester Cancer Research Center
AstraZeneca
Dainippon Sumitomo Pharma


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Breast Imaging Workstation
SecurView
Under Table Shield
3 Section Double Pivot Under Table Shield
New
Ultrasound Doppler System
Doppler BT-200

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.